Transactivation response DNA-binding protein 43 kDa (TDP-43) has been regarded as a major component of ubiquitin-positive/tau-negative inclusions of motor neurons and the frontotemporal cortices in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Neurofibrillary tangles (NFT), an example of tau-positive inclusions, are biochemically and morphologically distinguished from TDP-43-positive inclusions, and are one of the pathological core features of Alzheimer disease (AD). Although ALS/FTLD and AD are distinct clinical entities, they can coexist in an individual patient. Whether concurrence of ALS/FTLD-TDP-43 and AD-tau is incidental is still controversial, because aging is a common risk factor for ALS/FTLD and AD development. Indeed, it remains unclear whether the pathogenesis of ALS/FTLD is a direct causal link to tau accumulation. Recent studies suggested that AD pathogenesis could cause the accumulation of TDP-43, while abnormal TDP-43 accumulation could also lead to abnormal tau expression. Overlapping presence of TDP-43 and tau, when observed in a brain during autopsy, should attract attention, and should initiate the search for the pathological substrate for this abnormal protein accumulation. In addition to tau, other proteins including α-synuclein and amyloid β should be also taken into account as candidates for an interaction with TDP-43. Awareness of a possible comorbidity between TDP-43, tau and other proteins in patients with ALS/FTLD will be useful for our understanding of the influence of these proteins on the disease development and its clinical manifestation.
INTRODUCTION
Abnormal accumulation of transactivation response DNAbinding protein 43 kDa (TDP-43) is a hallmark of neurodegenerative processes in central neurons and glial cells, especially in most patients diagnosed with amyotrophic lateral sclerosis (ALS) or frontotemporal lobar degeneration (FTLD). [1] [2] [3] The major type of tau-negative FTLD is related to the presence of TDP-43-positive inclusions, now referred to as FTLD-TDP, forming a concept of TDP-43 proteinopathy along with the majority of cases with ALS. 4 Although it is still not clear how TDP-43 accumulation links to neuronal degeneration, [5] [6] [7] it is considered a potential marker indicating neuronal degenerative processes. It has been well documented that the cerebral neuronal degeneration associated with TDP-43 pathology could cause cognitive decline in patients with ALS/FTLD-TDP. 8, 9 Cognitive decline may also be linked to the additive presence of tau pathology, which is most commonly diagnosed as Alzheimer pathology. 10, 11 It is rather unusual if tau accumulation that meets the diagnostic criteria for Alzheimer disease (AD) is identified in patients withamyloid β) with TDP-43 will be discussed. A recent review by Spires-Jones provided clear and extended overview of multiple protein pathologies and their mutual interactions in neurodegenerative diseases. 23 This review aims to enhance our understanding of potential effects of ALS/FTLD-TDP-specific pathogenesis on the occurrence of multiple protein pathologies and on molecular interactions leading to protein accumulation.
CYTOPATHOLOGY AND TOPOGRAPHY OF TDP-43 IN ALS/FTLD-TDP
In patients with ALS, TDP-43 pathology generally presents as intraneuronal cytoplasmic inclusions (NCI). 1, 2 The motoneuronal NCI in the spinal cord or brainstem nucleus are characterized by rounded, skein-like and dot-like formations. 24, 25 The cortical NCI is well defined in appearance, with the majority being perinuclear curved or rounded in shape (Fig. 1) . 25 Neuropil pathology is limited to a few dot-like TDP-43-positive dystrophic neurites (DN). FTLD-TDP pathology recognized in ALS and the majority of cases with C9ORF72-mutated ALS/FTLD correspond to this cytopathologic type (predominantly NCI, few DN; the socalled "Mackenzie type B"). 26 Cases with granulin (GRN)-mutated FTLD exhibit FTLD-TDP pathology presenting as a large number of NCI and short DN (Mackenzie type A). [26] [27] [28] Whether these cytopathologic subtypes are defined by genetic background or whether they depend on which brain area is affected is still not resolved. Recent reports that revealed that the number of patients with ALS/FTLD (especially of C9ORF72-mutated cases) exhibiting a mixed pathology of TDP-43 (type A+B) is larger than previously thought suggests that genetic background is not the only factor determining cytopathologic subtype. 29 It seems that the TDP-43 pathology subtype does not follow a simple rule where one genetic factor leads to one pathological phenotype that then leads to one clinical manifestation. This may constitute a partial cause of clinicopathological heterogeneity in patients with ALS/FTLD. According to two previous reports regarding the topographical analyses of TDP-43 pathology in patients with ALS, the prevalence of TDP-43 pathology is substantially high (>80%) in the motor neurons of the spinal anterior horn, the hypoglossal nucleus, the inferior olivary nucleus, the primary motor cortex, and the brainstem reticular formation (Fig. 2) . It is modestly high (61-80%) in the red nucleus, the thalamus and the striatum. The prevalence is moderate (30-60%) in the amygdala, the temporal neocortex, the dentate gyrus and the cornu ammonis sector 1 (CA1). 30, 31 In the FTLD-TDP with a large number of NCI and few DN (Mackenzie type B), TDP-43 pathology occurs with quite high frequency (90-100%) in the amygdala, the dentate gyrus, the temporal cortex, the inferior olivary nucleus, the reticular formation, the thalamus and the striatum. The motor neurons in the primary motor cortex, the spinal cord, and the hypoglossal nucleus are affected by TDP-43 pathology in more than 50% of patients with FTLD-TDP with and without motor neuron disease (Fig. 2) . 32 Abnormal accumulation of TDP-43 spreads with a certain propensity along the disease-specific areas in the central nervous system, and might be associated with neuronal loss (Table 1) . 31, 35 However, it is still not established whether a stepwise spreading of TDP-43-positive 40 According to a report by Uchino et al., frontotemporal lobar degeneration with TDP-43 (FTLD-TDP) 32 and Alzheimer disease (AD), 33, 34 respectively. *A FTLD-TDP group pathologically presenting with a large number of neurocytoplasmic inclusions and few dystrophic neurites (Mackenzie type B) was surveyed. CA1, cornu ammonis sector 1; NA, not available. while it is not associated with clinical symptoms suggestive of FTLD or parkinsonian features. 44 There was one case report on TDP-43 pathology in a patient with heterozygote variant c.370C>G, p.Q124E in exon 4 of the microtubule-associated protein tau (MAPT). This case presented numerous TDP-43-positive NCI and DN in the hippocampus, the amygdala and the frontotemporal cortices. 45 In an animal model, Herman et al. demonstrated that the accumulation of TDP-43 was facilitated in overexpression of amyloid β 1-42 model mice, and was independent of the presence of tau pathology (Fig. 1) . 46 This suggests an overlap of biochemical pathways between ALS/FTLD and AD.
TDP-43 PATHOLOGY IN PROGRESSIVE SUPRANUCLEAR PALSY, CORTICOBASAL DEGENERATION AND ARGYROPHILIC GRAIN DISEASE
There are some reports that TDP-43 pathology can be detected in four-repeat tauopathies, such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and argyrophilic grain disease (AGD) (Fig. 1) . Uryu et al. Although the majority of TDP-43-positive inclusions were independent of tau-positive structures, partial colocalization of these two proteins was demonstrated in grain-like structures. 49 Arnold et al. reported that 40% of elderly individuals with TDP-43 pathology had argyrophilic grains (AG) pathology, while the prevalence of AG in elderly individuals without TDP-43 pathology was limited to less than 20%. 50 However, another study indicated no interaction between AG-tau and TDP-43 pathologies in elderly individuals. 51 
TAU AND OTHER PROTEIN PATHOLOGIES IN ALS/FTLD-TDP
The neuropathological analysis of the normal aging brain by Knopman et 55 This result is exemplified by the fact that aging is a common risk factor for the development of AD-tau pathology in normal elderly and ALS. 56, 57 The perforant pathway, representing major afferent projections of the hippocampus, is one of the components of Papez's circuit relevant to memory function. This pathway is well-known to be preferentially affected in patients with AD. [58] [59] [60] The involvement of this pathway has also been identified in patients with ALS. 61 The perforant pathway comprises two major components, one is the fiber connection from the medial entorhinal cortex to the intermediate lamina of the dentate molecular layer, and the other one is the fiber connection from the lateral entorhinal cortex to the outer lamina of the dentate molecular layer. 62 The former fiber connection is vulnerable in AD, whereas the latter is affected in patients with ALS. 63 Although this disease-specific degeneration that can be distinguished anatomically is probably relevant to the pathological accumulation of disease-specific proteins (tau accumulates in AD, while TDP-43 accumulates in ALS) in disease-specific susceptible neurons, these different proteins sometimes © 2017 Japanese Society of Neuropathology
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colocalize in the same neuron in a vulnerable area, such as the amygdala or the hippocampal complex, as reported in ALS, ALS/PDC, AD, and hippocampal sclerosis. 22, [63] [64] [65] Involvement of the olfactory pathway has been identified in patients with ALS/FTLD-TDP, Parkinson disease (PD) and AD. Odor impairments are observed in these patients even in the initial phase of the illness. Previous reports suggested that impaired odor identification is characteristic for ALS/FTLD 55 and AD, 66, 67 whereas impairment of odor detection is characteristic for PD. 55, 68 In ALS/FTLD-TDP, TDP-43 pathology along the olfactory pathway starts from the central regions including the hippocampus and the frontotemporal cortices, and subsequently spreads to peripheral regions (i.e., the olfactory bulb). Extensive cortical pathologies of TDP-43 may decrease the function of olfactory recognition in patients with ALS/FTLD-TDP. In contrast, α-synuclein pathology occurs in the olfactory bulb and extends to more central areas. This peripheral accentuation of α-synuclein pathology in PD may account for deficits of odor detection. AD-tau pathology begins slightly earlier in the central area (e.g., the hippocampus) than in the olfactory system. 69 Thus, the pattern of odor impairments in AD is central rather than peripheral. 66 At present, little is known about whether these proteins, TDP-43, tau and others, mutually promote the accumulation of each other in the same neuron (Fig. 1) . Robinson et al. investigated tau and TDP-43 pathologies of 33 cases with FTLD-tau and 45 cases with FTLD-TDP. In this report, the authors observed no interaction between tau and TDP-43 pathologies, because the TDP-43 pathology was found in only three out of 33 patients with FTLD-tau, and the tau pathology in the majority of patients with FTLD-TDP was limited to the hippocampal complex. The authors concluded that the development of tau and TDP-43 pathologies in patients with ALS/FTLD-TDP is independent. 70 Contrary to this hypothesis, there are some reports that AD-tau pathology occurs in patients with ALS/FTLD-TDP in association with the pathogenesis of FTLD-TDP. Bieniek et al. reported that four out of 48 patients with ALS/FTLD-TDP (including 11 patients with C9ORF72 mutations, 13 patients with GRN mutations and 24 sporadic patients) had a high level of tau pathology (Braak NFT stage of more than IV). All four patients had a mutation in C9ORF72. This suggests that the C9ORF72 mutation may promote the accumulation of tau in the ALS/FTLD-TDP brain. 71 An increased expression of tau mRNA is significant in the frontal gray matter in patients with ALS, especially those with cognitive impairments. 10 Interestingly, insoluble tau fragment banding patterns on Western blotting are different for patients with AD and those with ALS. The tau fragments occur in three isoforms in AD, whereas six fragments are found in patients with ALS. 72 Yang et al. observed that neuronal tau accumulation was marked in the entorhinal cortex and the amygdala in patients with ALS. Especially in patients with cognitive impairments, it extended to the anterior cingulate gyrus, the superior frontal gyrus, and the substantia nigra. Moreover, tuft-like astroglial tau accumulation was also encountered in these areas. Although this pathologically wide spread of tau accumulation in patients with ALS did not correlate with the severity of TDP-43 pathology, neurons harboring tau inclusions were notably demonstrating a loss of intranuclear staining for native TDP-43. 73 Vintilescu et al. demonstrated an abnormal accumulation of tau fragments in the spinal cord and the primary motor cortex of patients with ALS. 74, 75 In a recent investigation using an animal model, tau accumulation was increased in tau transgenic mice (P301L) with a GRN mutation in comparison with those without the mutation. 76 This suggests that progranulin reduction caused by GRN mutations may be causative for tau accumulation. Indeed, there were many previous reports on the presence of AD pathology in patients harboring GRN mutations. [77] [78] [79] [80] [81] [82] Abnormal tau aggregation was also reported in TDP-43-mutated mice. 83 Regarding human GRN mutation cases, Hosokawa et al. investigated four patients of FTLD with GRN mutations, and identified abnormal tau deposition in neurons, astroglia, and oligodendroglia in all patients. 84 In addition, they also reported that all four patients showed Lewy pathology. They concluded that reduction of progranulin densely linked to the onset of FTLD-TDP may be associated with expression of abnormal tau and α-synuclein (Fig. 1) . [84] [85] [86] However, in our series, no abnormal deposition of α-synuclein was detected in any of the four examined patients with FTLD with GRN mutations. In one out of 26 sporadic ALS/FTLD patients and two out of nine C9ORF72-mutated ALS/FTLD patients, α-synuclein pathology has been identified. 87 Cooper-Knock et al. reported that patients with ALS/FTLD with C9ORF72 mutations were characterized by significant neuronal loss of the substantia nigra and the absence of α-synuclein deposition. An α-synuclein pathology was found in only one out of 17 patients with C9ORF72-mutated ALS/FTLD. 88 α-synuclein expression may be less related to ALS/FTLD pathogenesis than tau expression (Fig. 1 ).
There are some recent studies using animal models that show that abnormal TDP-43 may exert an influence on tau accumulation and amyloid β metabolism. Gu et al. demonstrated that TDP-43 mislocalization into the cytoplasm may affect tau exon 10 splicing, which is linked to overexpression of four-repeat tau isoforms. 89, 90 This observation may relate to tau-positive tuft-like astrocytes in patients with ALS/FTLD, as described by Yang et al.
73
There was one report that identified predominant four-© 2017 Japanese Society of Neuropathology repeat tau isoform accumulation in the cerebral ischemic brain. 91 Because cerebral ischemia exerts a possible influence on TDP-43 accumulation, ischemic stress may be a causative factor common to the accumulation of both TDP-43 and four-repeat tau. 92 LaClair et al. reported that the nuclear depletion of TDP-43 could cause the decrement of fibril plaque deposition and enhance prefibrillar oligomeric deposition of amyloid β. They indicated that this prefibrillar deposition may exacerbate neurodegeneration. 93 In a TDP-43-overexpressed transgenic mouse with a familial mutation of the amyloid β precursor protein (APP) and presenilin 1 (PSEN1), abnormal tau accumulation and decrements in amyloid β plaque deposition were observed. This suggests that TDP-43 aggregation in the cytoplasm has an effect on regulating APP localization and tau accumulation (Fig. 1) . 94 A hierarchic relationship of protein deposition between TDP-43, tau and other proteins (including amyloid β and α-synuclein) in human subjects has still not been established (Fig. 1) . However, an increasing number of reports on animal models, as presented above, gradually build up the evidence of a mutual relationship of protein deposition. This would be, at least partly, helpful for the interpretation of the mechanism of protein overlap in the brain of patients with ALS/FTLD.
COEXISTENCE OF ARGYROPHILIC GRAINS AND TDP-43 IN ALS/FTLD-TDP
The AG are morphologically identified as small, spindleshaped or comma-like structures positive for silver staining (e.g., Gallyas stain) 95, 96 and biochemically composed of four-repeat tau. 97 AG sometimes occur in the elderly and are associated with neurodegenerative diseases including PSP, CBD, multiple system atrophy, and frontotemporal dementia and ALS with variable frequency. [98] [99] [100] However, the prevalence of coexistent AG in ALS/FTLD-TDP is quite inconsistent (7.7-37.8%). [98] [99] [100] Medial temporal atrophy is characteristic at least for some patients with ALS/FTLD-TDP. 101, 102 It may be accelerated by concomitant AG pathology. 103 Nonetheless, it remains unclear how abnormal AG-tau is associated with ALS/FTLD-TDP pathogenesis. As mentioned earlier, it is interesting that a recent study suggested a possible contribution of TDP-43 to four-repeat tau accumulation. It seems that AG-tau and TDP-43 are occasionally concurrent in the ALS/FTLD brain. 100 
CONCLUSION
Concurrent accumulation of TDP-43 and other proteins can occur in patients with ALS/FTLD-TDP. Despite increasing reports considering a relationship of TDP-43 with tau and others, at this moment, it is still unclear whether tau, α-synuclein and amyloid β accumulation in ALS/FTLD-TDP occur by chance, or whether the disease pathogenesis causes the accumulation of tau and other proteins. Likewise, the notion of a colocalized relationship between TDP-43 and other proteins in the same neuron remains to be established. If a wide spread of AD-tau pathology is observed in the autopsied brain with ALS/FTLD-TDP, the possibility of the additive accumulation of TDP-43 being enhanced by AD pathogenesis should be considered (Fig. 1) . Further investigations will be needed to clarify whether ectopic tau accumulation and its colocalization are intensified in TDP-43-susceptible areas, such as the medial temporal tip or spinal motor neurons, in patients with ALS/FTLD-TDP. 74, 104 The results of such studies will provide further evidence that ALS/FTLD-TDP pathogenesis could be associated with the facilitation of abnormal tau and the accumulation of other proteins. 
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